Amarin Stock Price, News & Analysis

Cyteir Therapeutics has appointed John F. Thero to its board of directors, expanding the board from eight to nine members. Thero, who brings over 30 years of experience in financial and operations roles, will chair the audit committee. He is recognized for leading Amarin through critical phases, including the launch of VASCEPA, and has received accolades such as Ernst & Young's Entrepreneur of the Year for Life Sciences. Thero expressed enthusiasm about contributing to Cyteir's growth, targeting advancements in their candidate CYT-0851 for oncology patients.

Amarin Corporation plc (NASDAQ:AMRN) reported preliminary unaudited revenue for 2021 of approximately $580 million, with Q4 revenue around $140 million, stabilizing a previous 8% decline. The company ended 2021 with $490 million in cash and no debt. Amarin's VAZKEPA was approved in Europe, and a fixed dose combination product with a statin is in development. Despite challenges from COVID-19 and generic competition, Amarin's U.S. net revenue is expected to be $575 million. The company is optimistic about future growth prospects in Europe and international markets, but is unable to provide 2022 revenue guidance due to uncertainties.

Amarin Corporation (NASDAQ: AMRN) announced that CEO Karim Mikhail will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 8:15 AM ET. The presentation will be available via a live webcast on the company's investor relations website, where it will also be archived for 30 days. Amarin is dedicated to transforming cardiovascular disease management through innovative research and clinical trials, with a commitment to advancing treatments beyond traditional therapies.

Amarin Corporation has presented new data on VASCEPA/VAZKEPA at the AHA Scientific Sessions 2021. The studies highlighted show that icosapent ethyl reduced total ischemic events by 32% in patients with prior peripheral artery disease (PAD). While safety profiles were generally consistent, there was an increased incidence of atrial fibrillation. Additionally, the PREPARE-IT 2 study did not meet its primary endpoint in evaluating efficacy for COVID-19 hospitalizations. Overall, these findings reinforce the cardiovascular benefits of VASCEPA while opening avenues for further research.

Amarin Corporation announced new findings on VASCEPA/VAZKEPA indicating a 32% reduction in total ischemic events for patients with prior peripheral artery disease (PAD). The results, presented at the AHA Scientific Sessions 2021, highlight the potential of icosapent ethyl in preventing major cardiovascular events. The analyses, part of the REDUCE-IT study, showed promising safety and efficacy profiles, with a 22% trend towards reduced first events. This reinforces VASCEPA's role as a key treatment for high-risk PAD patients.

Amarin Corporation plc (NASDAQ:AMRN) has announced that its CEO, Karim Mikhail, and CFO, Michael Kalb, will participate in two upcoming investor conferences. The Jefferies 2021 London Healthcare Conference is scheduled for November 16, 2021, at 1:40 pm GMT, featuring a corporate presentation by Mikhail. Additionally, the Piper Sandler 33rd Annual Virtual Healthcare Conference will be available on-demand starting November 22, 2021, with Mikhail participating in a fireside chat. Live audio webcasts can be accessed through the company’s investor relations website.

Amarin Corporation plc (NASDAQ: AMRN) announced the presentation of new VASCEPA®/VAZKEPA (icosapent ethyl) data at the AHA Scientific Sessions 2021 from November 13-15. Key findings highlight the drug's benefits for patients at risk of major cardiovascular events. The company will host a virtual exhibit booth, with additional programs including a Product Theater and Continuing Medical Education session, to enhance awareness of cardiovascular risk reduction. CEO Karim Mikhail emphasized the importance of engaging healthcare providers through digital strategies.

Amarin Corporation (NASDAQ: AMRN) reported Q3 2021 net revenue of $142.0 million, down 9% from Q3 2020, and $438.7 million for the nine months ending September 30, 2021, a 2% decline. The launch of VAZKEPA in Germany and regulatory submissions for reimbursement in ten European countries were significant highlights. Despite the competitive landscape with generics, Amarin retains approximately 83% of the U.S. icosapent ethyl market. The company ended Q3 with $517.9 million in cash. Ongoing efforts on market access and digital strategies aim to enhance VASCEPA demand.

BYOMass has appointed Dr. Declan Doogan and Dr. Stephen Hoffman to its Board of Directors. Dr. Doogan, a pharmaceutical veteran, previously led drug development at Pfizer and was Head of R&D at Amarin Corporation. Dr. Hoffman brings extensive experience from Aerpio Pharmaceuticals and has served on multiple biotech boards. Their expertise is expected to guide BYOMass’s innovative pipeline targeting the TGF-β superfamily, potentially improving therapies for diseases with high unmet medical needs.